HUMAW

Humacyte, Inc.

HUMAW · CIK 1818382 · Annual (10-K) · Last 5 years

Financial Trends

Revenue
20202024
Net Income−$149M
20202024
Operating CF−$98M
20202024
Free Cash Flow−$100M
20202024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Revenue—————
Cost of Revenue—————
Gross Profit—————
R&D Expense$0.1B$0.1B$0.1B$0.1B—
SG&A Expense—————
Operating Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B
Net Income$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-1.26$-1.07$-0.12$-0.66—
EPS (Diluted)$-1.26$-1.07$-0.12$-0.66—

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Total Assets$0.1B$0.1B$0.2B$0.3B$0.1B
Current Assets$0.0B$0.1B$0.2B$0.2B$0.0B
Cash & Equivalents$0.0B$0.1B$0.1B$0.2B$0.0B
Total Liabilities$0.2B$0.1B$0.1B$0.2B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$-0.1B$0.0B$0.1B$0.1B$0.0B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Operating Cash Flow$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B
Investing Cash Flow$-0.0B$-0.0B$0.0B$-0.0B$-0.1B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B—
Financing Cash Flow$0.1B$0.0B$-0.0B$0.3B$0.1B
← Companies